THE IMPACT OF MOUNJARO ON WEIGHT LOSS AND QUALITY OF LIFE
DOI:
https://doi.org/10.61164/jyvyyv93Keywords:
Brazil; Quality of life; Obesity; TizerpatideAbstract
Obesity is one of the major public health challenges in Brazil, associated with several comorbidities. This study presents an integrative literature review on the impact of tirzepatide (Mounjaro) on weight loss and quality of life. The methodology included a systematic search in PubMed, Embase, Cochrane, SciELO, and Anvisa documents, from 2018 to 2025, using descriptors 'tirzepatide', 'obesity', 'quality of life', and 'SURMOUNT'. Randomized clinical trials, observational studies, and systematic reviews were included, while preclinical and case
reports were excluded. The analysis showed that tirzepatide leads to mean reductions of up to 22.8 kg at 72 weeks, surpassing semaglutide, in addition to improvements in metabolic and cardiovascular parameters. It also demonstrated positive impact on quality of life measures (EQ-5D, SF-36). It is concluded that tirzepatide is a promising therapy, provided it is integrated with public health policies and multidisciplinary care.
Downloads
References
CONSELHO REGIONAL DE MEDICINA DA PARAÍBA. Artigo | Tirzepatida: eficaz contra diabetes e obesidade. João Pessoa, 3 set. 2024. Acesso em: 29 set. 2025.
FERREIRA, Vanessa Alves; MAGALHÃES, Rosana. Obesidade no Brasil: tendências atuais. Revista Portuguesa de Saúde Pública, v. 24, n. 2, p. 71-81, 2006. Acesso em: 30 set. 2025
FREITAS, Túlio Martins; DE OLIVEIRA MOTA, Frederico Lucas; PINHEIRO, Abilail Paula. Terapias farmacológicas para tratar obesidade: análise de efeito e eficácia. Revista Foco, São Paulo, v. 17, n. 10, p. e6522-e6522, 2024. Acesso em: 29 set. 2025. DOI: https://doi.org/10.54751/revistafoco.v17n10-082
INTERDISCIPLINAR EM SAÚDE. O uso de tirzepatida no combate à obesidade: uma análise. 2024. Acesso em: 22 set. 2025.
LAGO, L. M. O uso da tirzepatida no tratamento da obesidade: revisão. Brazilian Journal of Interdisciplinary Health Sciences, [S.l.], 2025. Acesso em: 25 de set. 2025
OLHAR DA SAÚDE. Mounjaro® é aprovado pela Anvisa para tratamento da obesidade no Brasil. 9 jun. 2025. Acesso em: 05 de out. 2025.
SILVA, J. R.; LIMA, P. A.; ANDRADE, C. S. Avaliação do efeito da tirzepatida na perda de peso: revisão sistemática. Revista Brasileira de Obesidade, Nutrição e Emagrecimento, São Paulo, v. 19, n. 123, p. 45-56, 2025. Acesso em: 25 de set. 2025.
SINGH, Amit Kumar. The Science Behind Mounjaro and Wegovy for Weight Loss. [S.l.: s.n.], 2023. Acesso em: 22 de set. 2025.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Geraldo Henrique Kloss de Mello, Matheus Carvalho dos Santos, Heloisa Silva Zamerin, Willemberg Nicolai
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
Authors retain copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Creative Commons Attribution License, which permits the sharing of the work with proper acknowledgment of authorship and initial publication in this journal;
Authors are authorized to enter into separate, additional agreements for the non-exclusive distribution of the version of the work published in this journal (e.g., posting in an institutional repository or publishing it as a book chapter), provided that authorship and initial publication in this journal are properly acknowledged, and that the work is adapted to the template of the respective repository;
Authors are permitted and encouraged to post and distribute their work online (e.g., in institutional repositories or on their personal websites) at any point before or during the editorial process, as this may lead to productive exchanges and increase the impact and citation of the published work (see The Effect of Open Access);
Authors are responsible for correctly providing their personal information, including name, keywords, abstracts, and other relevant data, thereby defining how they wish to be cited. The journal’s editorial board is not responsible for any errors or inconsistencies in these records.
PRIVACY POLICY
The names and email addresses provided to this journal will be used exclusively for the purposes of this publication and will not be made available for any other purpose or to third parties.
Note: All content of the work is the sole responsibility of the author and the advisor.
